Title:
MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2020/147802
Kind Code:
A1
Abstract:
Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
Inventors:
CHEN JIANYONG (CN)
ZHOU YUNLONG (CN)
TANG GUOZHI (CN)
WU CHENGZHE (CN)
ZHAO LEILEI (CN)
JIAO LINGLING (CN)
SHENG BINGHUA (CN)
WANG SHAOMENG (US)
YANG CHAO-YIE (US)
CHEN HAO (CN)
HU WENLIANG (CN)
JING YU (CN)
ZHOU YUNLONG (CN)
TANG GUOZHI (CN)
WU CHENGZHE (CN)
ZHAO LEILEI (CN)
JIAO LINGLING (CN)
SHENG BINGHUA (CN)
WANG SHAOMENG (US)
YANG CHAO-YIE (US)
CHEN HAO (CN)
HU WENLIANG (CN)
JING YU (CN)
Application Number:
PCT/CN2020/072565
Publication Date:
July 23, 2020
Filing Date:
January 17, 2020
Export Citation:
Assignee:
ASCENTAGE PHARMA SUZHOU CO LTD (CN)
UNIV MICHIGAN REGENTS (US)
ASCENTAGE PHARMA GROUP CORP LTD (CN)
UNIV MICHIGAN REGENTS (US)
ASCENTAGE PHARMA GROUP CORP LTD (CN)
International Classes:
C07D513/20; A61K31/553; A61P35/00; C07D498/08; C07D515/20
Domestic Patent References:
| WO2017147410A1 | 2017-08-31 | |||
| WO2018183418A1 | 2018-10-04 | |||
| WO2016033486A1 | 2016-03-03 | |||
| WO2019046150A1 | 2019-03-07 | |||
| WO2019036575A1 | 2019-02-21 | |||
| WO2017147410A1 | 2017-08-31 |
Foreign References:
| US5093330A | 1992-03-03 |
Other References:
DANIALKORSMEYER, CELL, vol. 116, 2004, pages 205 - 219
ADAMSCORY, ONCOGENE, vol. 26, 2007, pages 1324 - 1337
WILLIS ET AL., SCIENCE, vol. 315, 2007, pages 856 - 859
BEROUKHIM ET AL., NATURE, vol. 463, 2010, pages 899 - 905
KIRKIN ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1644, 2004, pages 229 - 249
AMUNDSON ET AL., CANCER RESEARCH, vol. 60, 2000, pages 6101 - 6110
WEI ET AL., CANCER CHEMOTHER PHARMACOL, vol. 62, 2008, pages 1055 - 1064
WERTZ ET AL., NATURE, vol. 471, 2011, pages 110 - 114
M. CAIRA ET AL., J. PHARMACEUT. SCI., vol. 93, no. 3, 2004, pages 601 - 611
TONDER ET AL., AAPS PHARM. SCI. TECH., vol. 5, no. 1, 2004
A.L. BINGHAM ET AL., CHEM. COMMUN., 2001, pages 603 - 604
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING CO.
See also references of EP 3781574A4
ADAMSCORY, ONCOGENE, vol. 26, 2007, pages 1324 - 1337
WILLIS ET AL., SCIENCE, vol. 315, 2007, pages 856 - 859
BEROUKHIM ET AL., NATURE, vol. 463, 2010, pages 899 - 905
KIRKIN ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1644, 2004, pages 229 - 249
AMUNDSON ET AL., CANCER RESEARCH, vol. 60, 2000, pages 6101 - 6110
WEI ET AL., CANCER CHEMOTHER PHARMACOL, vol. 62, 2008, pages 1055 - 1064
WERTZ ET AL., NATURE, vol. 471, 2011, pages 110 - 114
M. CAIRA ET AL., J. PHARMACEUT. SCI., vol. 93, no. 3, 2004, pages 601 - 611
TONDER ET AL., AAPS PHARM. SCI. TECH., vol. 5, no. 1, 2004
A.L. BINGHAM ET AL., CHEM. COMMUN., 2001, pages 603 - 604
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING CO.
See also references of EP 3781574A4
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: